Sanjay Rajagopalan Selected Research

Angiotensin Receptor Antagonists

5/2013	Aliskiren effect on plaque progression in established atherosclerosis using high resolution 3D MRI (ALPINE): a double-blind placebo-controlled trial.
3/2006	Aldosterone receptor antagonists for heart failure: current status, future indications.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sanjay Rajagopalan Research Topics

Disease

38	Inflammation (Inflammations) 01/2022 - 09/2003
32	Cardiovascular Diseases (Cardiovascular Disease) 07/2022 - 09/2003
32	Atherosclerosis 01/2022 - 05/2002
22	Insulin Resistance 11/2020 - 09/2007
18	Heart Failure 05/2021 - 03/2003
17	Type 2 Diabetes Mellitus (MODY) 01/2022 - 02/2009
12	Hypertension (High Blood Pressure) 03/2022 - 08/2003
11	Peripheral Arterial Disease 01/2020 - 09/2002
10	Obesity 03/2022 - 09/2007
9	Chronic Renal Insufficiency 01/2020 - 11/2003
8	Atherosclerotic Plaque (Atheroma) 01/2022 - 11/2009
8	Weight Loss (Weight Reduction) 01/2022 - 09/2007
8	Myocardial Infarction 01/2021 - 09/2003
6	Fibrosis (Cirrhosis) 01/2022 - 09/2003
6	Diabetes Mellitus 01/2020 - 11/2011
6	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2018 - 08/2003
5	Stroke (Strokes) 11/2021 - 09/2009
5	Neoplasms (Cancer) 01/2020 - 07/2007
5	Ischemia 12/2012 - 02/2002
4	Atrial Fibrillation 12/2021 - 07/2009
4	Intermittent Claudication 10/2011 - 10/2003
3	Hyperglycemia 01/2022 - 10/2014
3	Overweight 01/2019 - 04/2004
3	Body Weight (Weight, Body) 01/2016 - 01/2010
2	Vascular Diseases (Vascular Disease) 01/2022 - 04/2008
2	Arteritis 01/2021 - 01/2020
2	Lung Diseases (Lung Disease) 01/2020 - 11/2019
2	Chronic Obstructive Pulmonary Disease (COPD) 01/2020 - 10/2017
2	Dyslipidemias (Dyslipidemia) 01/2018 - 04/2008
2	Acute Coronary Syndrome 06/2017 - 07/2004
2	Hypertrophy 06/2015 - 09/2003
2	Weight Gain 04/2015 - 08/2012
2	Ventricular Remodeling 12/2013 - 07/2012
2	Metabolic Diseases (Metabolic Disease) 08/2013 - 01/2013
2	Infarction (Infarctions) 12/2012 - 07/2004

Drug/Important Bio-Agent (IBA)

37	Particulate MatterIBA 01/2021 - 06/2004
16	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 05/2011
10	LipidsIBA 01/2022 - 01/2006
10	Biomarkers (Surrogate Marker)IBA 12/2021 - 10/2005
9	Insulin (Novolin)FDA Link 12/2019 - 01/2010
9	IncretinsIBA 01/2018 - 01/2013
7	CalciumIBA 07/2022 - 08/2005
7	Biological ProductsIBA 01/2021 - 07/2007
7	Air Pollutants (Pollutants, Air)IBA 01/2019 - 02/2009
6	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022 - 10/2005
6	GadoliniumIBA 01/2019 - 11/2009
6	Pharmaceutical PreparationsIBA 01/2019 - 08/2011
6	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2010 - 01/2003
5	Proteins (Proteins, Gene)FDA Link 01/2018 - 06/2004
5	Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA 09/2017 - 05/2002
4	CholesterolIBA 03/2022 - 10/2014
4	Lipoproteins (Lipoprotein)IBA 01/2022 - 07/2007
4	Apolipoproteins E (ApoE)IBA 01/2022 - 12/2005
4	Messenger RNA (mRNA)IBA 01/2022 - 12/2009
4	C-Reactive ProteinIBA 12/2021 - 07/2007
4	AntioxidantsIBA 01/2018 - 10/2002
4	OzoneIBA 01/2016 - 08/2013
4	Peptides (Polypeptides)IBA 01/2015 - 03/2011
3	Glucagon-Like Peptide-1 ReceptorIBA 01/2022 - 01/2022
3	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2022 - 03/2016
3	Triglycerides (Triacylglycerol)IBA 01/2022 - 08/2003
3	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2022 - 02/2013
3	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2020 - 11/2002
3	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 03/2019 - 11/2011
3	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2017 - 01/2014
3	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2016 - 01/2010
3	LeptinIBA 01/2016 - 09/2007
3	Thioctic Acid (Lipoic Acid)IBA 01/2015 - 01/2010
3	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 05/2013 - 03/2003
3	Angiotensin IIIBA 03/2011 - 07/2004
3	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2008 - 05/2003
3	Mineralocorticoid Receptor AntagonistsIBA 03/2006 - 05/2002
3	Nitroglycerin (Dynamite)FDA LinkGeneric 11/2005 - 02/2002
3	AldosteroneIBA 07/2004 - 03/2003
2	Uric Acid (Urate)IBA 01/2022 - 01/2022
2	ApolipoproteinsIBA 12/2021 - 12/2009
2	CreatinineIBA 05/2021 - 03/2003
2	omega-Chloroacetophenone (Mace)IBA 01/2021 - 01/2020
2	Environmental Pollutants (Pollutants, Environmental)IBA 11/2020 - 11/2015
2	TroponinIBA 01/2020 - 12/2019
2	oxidized low density lipoproteinIBA 03/2019 - 01/2006
2	MicroRNAs (MicroRNA)IBA 12/2018 - 01/2016
2	AerosolsIBA 01/2018 - 10/2014
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2018 - 11/2003
2	N- (3,5- bis(trifluoromethyl)phenyl)- 5- chloro- 2- hydroxybenzamideIBA 01/2018 - 10/2014
2	EnzymesIBA 01/2018 - 06/2010
2	Spironolactone (Aldactone)FDA LinkGeneric 09/2017 - 03/2006
2	CCR2 ReceptorsIBA 01/2017 - 01/2014
2	SootIBA 01/2016 - 04/2014
2	NADPH Oxidases (NAD(P)H oxidase)IBA 12/2015 - 09/2009
2	CytokinesIBA 11/2015 - 06/2015
2	Therapeutic UsesIBA 01/2015 - 01/2010
2	LDL Lipoproteins (beta Lipoproteins)IBA 10/2014 - 01/2006
2	Angiotensin Receptor AntagonistsIBA 05/2013 - 03/2006
2	Hormones (Hormone)IBA 02/2013 - 04/2008

Therapy/Procedure

21	Therapeutics 12/2021 - 11/2002
5	Renal Dialysis (Hemodialysis) 12/2013 - 10/2006
3	Drug Therapy (Chemotherapy) 01/2022 - 01/2020
3	Precision Medicine 01/2019 - 04/2012
2	Secondary Prevention 06/2017 - 04/2008